Baxter looks to bring Immuno fibrin sealant to U.S. market following $715 mil. acquisition.
This article was originally published in The Gray Sheet
Executive Summary
BAXTER/IMMUNO COMBO COULD PROVIDE FIBRIN SEALANT TO U.S. MARKET, Baxter indicated during an Aug. 29 teleconference. The conference call followed the announcement by Baxter International and Orth, Austria-based Immuno International AG that Baxter will acquire the plasma derived medical products company over a period of three years for approximately $715 mil.